Study presented at ATTD 2024 is the first of a
planned series examining the impact of Dario's integrated
cardiometabolic solution as a means to address weight and diabetes
with or without a GLP-1
Additional research presented demonstrated
Dario's ability to improve awareness of the importance of flu
vaccines in member with Type 2 diabetes
NEW
YORK, March 12, 2024 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global
digital therapeutics (DTx) market, announced today two new clinical
studies presented at the 17th International Conference
on Advanced Technologies and Treatments for Diabetes (ATTD) 2024,
held March 6 – 9 in Florence, Italy.
Examining evolving standards for metabolic health: Improving
outcomes with or without medication
The introduction of GLP-1s as an effective tool for both weight
loss and diabetes management is evolving the standards of care for
metabolic health conditions. Dario's cardiometabolic solution
integrates digital tools, connected devices and intelligent
technologies to deliver a personalized and integrated experience to
help drive better outcomes through effective behavior change.
Today, members can utilize the Dario solution with or without a
GLP-1 medication and receive support tailored to their unique
need.
To better understand the impact of the Dario solution on the
populations eligible for a GLP-1, Dario is conducting a series of
studies looking at the related clinical outcomes of those members
taking a GLP-1 and those without the medication. The first study
presented at ATTD analyzed the data of members engaged in Dario's
cardiometabolic solution to manage pre-diabetes, a condition that
requires weight loss and regulation of A1c.
The study looked at the data of 6,963 members living with
pre-diabetes who used Dario's smart blood glucose meter alongside
weight tracking to track their clinical measurements and engage in
digital activities such as meal tagging.
Results included a 6.38% reduction in weight for members with a
baseline BMI of 30 and above and an overall reduction in blood
glucose levels, with average blood glucose levels remaining below
140 mg/dL for one year. Notably, users who consistently engaged in
meal tagging activities, with an average frequency exceeding five
times per month, experienced statistically significant and stronger
reductions in average weight. The results are significant for
people living with pre-diabetes, showing the self-management of
pre-diabetes with a single digital platform can drive the behavior
change necessary to reduce the risk of Type 2 diabetes.
"We are thrilled with the results on Dario's ability to
meaningfully impact the clinical measures associated with
pre-diabetes, helping our members adopt the healthier behaviors
necessary to reduce their risks of Type 2 diabetes. This data
clearly shows the value of a single approach to supporting the
weight loss and blood glucose improvements needed to help make
those changes possible," said Yifat Hershcovitz, PhD, Vice
President of Clinical and Scientific Affairs at Dario.
"Reducing the risk of Type 2 diabetes is incredibly important to
help lower the risk of progression to the more serious and costly
disease of Type 2 diabetes and requires a holistic approach.
Dario's ability to deliver digital behavior change with an
integrated solution across clinical and behavioral needs is a
powerful combination that delivers results for our members and our
partners," said Omar Manejwala, MD,
Chief Medical Officer at Dario.
Improving awareness of influenza (flu) vaccines in members
with Type 1 and Type 2 diabetes
A second Dario study presented at ATTD evaluated the
effectiveness of Dario's digital health solution as a means to
improve flu vaccine awareness and rates. To conduct the analysis, a
group of 64,904 Dario members with Type 1 or Type 2 diabetes were
randomly assigned to one of three test groups assigned to receive
flu vaccine nudge intervention messaging: a previously published
intervention of one message a month; an adapted intervention with
revised cadence of 2 – 3 messages a month based on Dario platform
user experience; and a group with no intervention (Control).
Members who received messages as part of the first two test
groups, both the published intervention group and the adapted
intervention group receiving more frequent communications, showed a
higher self-reported rate of flu vaccinations versus the control
group. Those members in the adapted intervention group demonstrated
a higher self-reported follow-through vaccination rate. This group
also reported significantly greater awareness of the risks of
influenza and greater recollection of educational content.
Overall, the study signals that digital health platforms with an
established relationship in existing member bases can play an
effective role in supporting flu vaccination campaigns and
outcomes.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital
therapeutics (DTx) company revolutionizing how people with chronic
conditions manage their health through a user-centric multi-chronic
condition platform. Our platform and suite of solutions deliver
personalized and dynamic interventions driven by data analytics and
one-on-one coaching for diabetes, hypertension, weight management,
musculoskeletal pain, and behavioral health.
Our user-centric platform offers people continuous and
customized care for health, disrupting the traditional episodic
approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention, and
results. Making the right thing to do the easy thing to
do.
Dario provides its highly user rated solutions globally to
health plans and other payors, self-insured employers, providers of
care and directly to consumers. To learn more about
DarioHealth and its digital health solutions, or for more
information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the potential benefits to be realized through its digital platform
for pre-diabetes patients. Without limiting the generality of the
foregoing, words such as "plan," "project," "potential," "seek,"
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parella
Investor Relations Manager
+315-378-6922
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
View original
content:https://www.prnewswire.com/news-releases/new-research-from-dario-demonstrates-ability-to-deliver-improved-health-outcomes-with-integrated-solution-for-members-managing-weight-and-blood-glucose-with-or-without-glp-1-medications-302086552.html
SOURCE DarioHealth Corp.
